SEED Therapeutics Appoints Dr. Bill Desmarais as Chief Financial Officer and Chief Business Officer
KING OF PRUSSIA, Pa., June 09, 2025 (GLOBE NEWSWIRE) -- SEED Therapeutics Inc. ("SEED"), a biotechnology company pioneering targeted protein degradation (TPD) through the discovery of innovative molecular glues and bifunctional degraders, today announced the appointment of Dr. Bill Desmarais, Ph.D., MBA, as Chief Financial Officer and Chief Business Officer.
"Bill's appointment comes at a pivotal time as SEED advances its differentiated pipeline into clinical trials and expands global strategic partnerships,' said Dr. Lan Huang, Co-Founder, Chairman, and CEO of SEED. 'His extensive experience in high-impact transactions and strategic licensing will strengthen SEED's ability to accelerate breakthrough therapies in oncology, neurodegeneration, and immunology through our proprietary RITE3™ TPD platform. This appointment underscores SEED's commitment to delivering transformative treatments for patients, partners, and shareholders in 2025 and beyond.'
Dr. Desmarais brings more than two decades of leadership in finance, business development, and strategic operations within the biopharma and biotech industries. He previously served as Chief Business Officer at Alchemab Therapeutics and TScan Therapeutics, as well as Vice President of Business Development at Momenta Pharmaceuticals, where he played a critical role in the company's $6.5 billion acquisition by Johnson & Johnson. Earlier in his career, he spent over a decade at Eli Lilly and Company in Search & Evaluation and Corporate Business Development, advancing global partnerships and pipeline expansion. Dr. Desmarais holds a Ph.D. in Biophysics and Structural Biology from Brandeis University, an MBA from the MIT Sloan School of Management, and a B.S. in Biology from Purdue University.
"I am excited to join SEED at this transformative moment, working alongside an exceptional team of leaders and innovators,' said Dr. Desmarais. 'I look forward to collaborating with Dr. Lan Huang and her distinguished SEED Co-Founders—Nobel Laureate Avram Hershko and HHMI Investigators Michele Pagano and Ning Zheng—who are at the forefront of breakthrough research in targeted protein degradation. SEED's world-class translational scientists, drug developers, and deeply engaged Board of Directors bring unparalleled expertise across science, finance, risk management, law, and governance. Together, we will advance SEED's groundbreaking strategy, forge key alliances, and drive meaningful impact for patients and stakeholders worldwide.'
About SEED TherapeuticsSEED Therapeutics is a biotechnology company dedicated to advancing targeted protein degradation (TPD) through the discovery of novel molecular glues and bifunctional degraders. Powered by its proprietary RITE3™ TPD platform, SEED is developing a pipeline of first-in-class degraders aimed at traditionally undruggable targets across oncology, neurodegeneration, immunology, and virology. Strategic collaborations with industry leaders Eli Lilly and Company and Eisai Co., Ltd. further reinforce SEED's commitment to developing innovative therapies, with its lead RBM39 degrader program expected to enter clinical trials in 2025. For more information, visit seedtherapeutics.com.
Investor Contact: IR@seedtherapeutics.comMedia Contact: PR@seedtherapeutics.comSign in to access your portfolio
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
15 minutes ago
- Yahoo
Poor Communication Costs the Tech Industry $50 Billion: ParallelStaff Launches Initiative to Bridge Global Gaps
DALLAS, TX, June 11, 2025 (GLOBE NEWSWIRE) -- ParallelStaff, a Dallas-based nearshore outsourcing and technology services provider, has announced a new initiative to address one of the tech industry's most costly and overlooked challenges: communication failures in IT projects. With estimates suggesting that ineffective collaboration leads to more than $50 billion in annual losses, the company focuses on improving team alignment and project execution through strategic nearshore Studies have shown that 50% of IT projects fail due to breakdowns in communication, often rooted in unclear goals, inconsistent feedback, and misaligned stakeholder expectations. These issues are particularly pronounced in distributed and cross-border development environments. As software development outsourcing continues to grow, particularly among companies seeking speed and scalability, the ability to maintain effective communication has emerged as a mission-critical component of tech project management. 'Communication challenges are not just a soft-skill issue, they're a bottom-line problem,' said Miguel Hernandez, Vice President of Operations at ParallelStaff. 'Budget overruns, delayed releases, and even project abandonment are symptoms of deeper alignment issues. Our initiative is about restoring clarity and continuity in global development teams.' A Cost Hidden in Plain Sight Despite increased investment in agile development practices, companies are still facing major hurdles when it comes to coordinating between internal and external teams. The complexity of modern software systems, combined with geographic and linguistic barriers, often results in remote collaboration breakdowns that go unaddressed until project goals are missed or resources are exhausted. When communication fails, companies often experience cascading effects: shifting requirements, duplicated efforts, missed dependencies, and frequent rework. These outcomes are not just inconvenient; they are the leading indicators of large-scale IT project failure. Tech executives have begun to recognize that even the best tools and methodologies cannot compensate for poor communication structures. 'Effective tech project management requires more than task tracking,' Hernandez explained. 'It demands real-time clarity across diverse teams, especially when leveraging software development outsourcing. The earlier we close those gaps, the greater the chance of delivering successful outcomes.' The Case for Nearshore Outsourcing To solve these communication bottlenecks, ParallelStaff is promoting a nearshore outsourcing model designed specifically to enable stronger collaboration and execution. Unlike offshore development models that operate in distant time zones with greater cultural differences, nearshore teams share similar working hours and business practices, making real-time engagement far more attainable. With development professionals located in Latin America and fluent in English, ParallelStaff's nearshore outsourcing approach facilitates direct collaboration during core business hours. This structure supports daily standups, rapid iterations, and smoother cross-functional integration, which are cornerstones of software development best practices. 'Nearshore teams allow for faster resolution of blockers, more interactive sprint planning, and tighter feedback loops,' said Hernandez. 'This alignment is particularly critical for companies adopting or scaling agile development frameworks.' A Scalable, Communication-First Solution At the heart of ParallelStaff's approach is a focus on pairing technical excellence with communication competence. The company recruits, vets, and places developers based on both their coding expertise and their ability to operate effectively within client workflows and cultures. Rather than offering generalized outsourcing solutions, ParallelStaff tailors its engagements to match the client's organizational structure and project lifecycle. Developers are embedded into existing teams to ensure shared ownership and proactive participation, an approach that enhances accountability and reduces misinterpretations that lead to costly rework. Key benefits of ParallelStaff's model include:• Seamless integration with agile development challenges and workflows• Reduced friction in remote collaboration due to time zone and language alignment• Access to a curated network of experienced software professionals• A flexible model that scales as business needs evolve 'We're seeing that tech leaders don't just want headcount, they want contributors who can communicate, collaborate, and deliver within the context of their strategy,' Hernandez said. 'That's where we focus our energy.' Moving from Risk to Readiness As businesses scale digital operations and embrace hybrid work environments, communication is no longer a soft skill, it's a critical infrastructure component. ParallelStaff's initiative is positioned to help organizations identify risk areas early and implement sustainable solutions that reduce the likelihood of IT project failure. In an industry where delays and inefficiencies can cost millions, aligning development resources through effective communication isn't just a competitive advantage; it's an operational necessity. To assist companies in addressing communication breakdowns and improving project performance, ParallelStaff is offering complimentary strategy calls with its technical team. During these sessions, stakeholders can assess their current development structures, identify potential risks, and explore how a nearshore model can enhance execution and delivery. About ParallelStaff ParallelStaff is a Dallas, Texas–based company that provides nearshore outsourcing and IT staffing solutions for businesses seeking scalable, high-performance development teams. Focusing on English-fluent, culturally aligned professionals, ParallelStaff helps clients improve communication, agility, and execution in complex software Media Contact Company Name: ParallelStaff Contact Person: Miguel Hernandez Email: hello@ Phone: (214) 945 8202 Country: United States Website:
Yahoo
18 minutes ago
- Yahoo
RadNet Secures $100 Million Incremental Term Loan to Fund Acquisitions and Corporate Initiatives
LOS ANGELES, June 11, 2025 (GLOBE NEWSWIRE) -- RadNet, Inc. (NASDAQ: RDNT) ('RadNet'), a national leader in providing high-quality, cost-effective, fixed-site outpatient diagnostic imaging services, today announced that it has entered into Incremental Amendment No. 2 (the 'Second Amendment') to its Third Amended and Restated First Lien Credit and Guaranty Agreement, as amended (the 'Existing Credit Agreement' and, as amended by the Second Amendment, the 'Credit Agreement'). Pursuant to the Second Amendment, Barclays Bank PLC, as lender, committed to provide RadNet an incremental term loan in the aggregate principal amount of $100.0 million (the '2025 Incremental Term Loan'), which will be added to and form a part of the existing term loan under the Existing Credit Agreement (the 'Existing Term Loan,' together with the 2025 Incremental Term Loan, the 'Term Loan'). The 2025 Incremental Term Loan will mature on April 18, 2031—coincident with the maturity date of the $868.4 million balance of the Existing Term Loan under the Existing Credit Agreement. Quarterly payments of principal on the Term Loan will be approximately $2.4 million compared to approximately $2.2 million prior to the entry of the Second Amendment. All other terms and covenants of the Credit Agreement (as amended by the Second Amendment) remain unchanged. The proceeds of the 2025 Incremental Term Loan will be used to finance future acquisitions and for other general corporate purposes, providing RadNet with additional flexibility to pursue strategic growth opportunities across its national imaging center network and technology platforms. Mark Stolper, Executive Vice President and Chief Financial Officer of RadNet, commented, 'We appreciate the continued support of Barclays and our relationship banks and term-loan lenders. This incremental financing increases our capacity to execute on a pipeline of acquisition opportunities while maintaining our conservative capital structure. The proceeds of approximately $100 million adds to the $717 million cash balance as of March 31, 2025, positioning us to advance our growth strategy and create long-term value for our stockholders.'RadNet, Inc. is a leading national provider of freestanding, fixed-site diagnostic imaging services in the United States based on the number of locations and annual imaging revenue. RadNet has a network of 401 owned and/or operated outpatient imaging centers. RadNet's imaging center markets include Arizona, California, Delaware, Florida, Maryland, New Jersey, New York and Texas. In addition, RadNet provides radiology information technology and artificial intelligence solutions marketed under the DeepHealth brand, teleradiology professional services and other related products and services to customers in the diagnostic imaging industry. Together with contracted radiologists, and inclusive of full-time and per diem employees and technologists, RadNet has a total of over 11,000 employees. For more information, visit Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
24 minutes ago
- Yahoo
Topeka's KMC Dermatology Is First in Kansas to Offer Nonsurgical GentleCure™ Treatment Option for Common Skin Cancer
BURR RIDGE, Ill., June 11, 2025 /PRNewswire/ -- SkinCure Oncology, the industry leader in providing a comprehensive cancer center model for the delivery of Image-Guided Superficial Radiation Therapy (Image-Guided SRT or IGSRT) for the treatment of nonmelanoma skin cancer (NMSC), presented to dermatology patients and professionals as the GentleCure Experience™, today announced its first availability in Kansas at an event at Topeka's KMC Dermatology. Image-Guided SRT is the only treatment for nonmelanoma skin cancer (basal and squamous cell carcinoma) that uses ultrasound imaging to help clinicians direct low-level x-rays to targeted areas of the skin, killing cancer cells. For patients treated with Image-Guided SRT, the cure rate (freedom from recurrence at six years) has been shown to be greater than 99 percent, with researchers reporting that for appropriately selected early-stage nonmelanoma skin cancers, Image-Guided SRT is a clinically equivalent alternative to Mohs surgery and statistically significant in superiority to non-Image-Guided SRT. Dr. Joseph Gadzia of KMC Derm noted, "More than 26,000 individuals in Kansas are expected to be diagnosed with nonmelanoma skin cancer this year. We know that sun exposure is the main cause of this type of cancer but there are other factors as well. For those who have been diagnosed with nonmelanoma skin cancer, we now offer a nonsurgical treatment option which we call the GentleCure Experience, and we are proud to be the first practice in the state to offer it." Dr. Gadzia also added, "While most common skin cancers have been treated with Mohs surgery, this newer treatment option achieves close to the same success rate with no surgery, no surgical scarring, and no bleeding. As of this past April, more than 100,000 patients have been successfully treated with Image-Guided SRT in the United States." Other speakers included Dr. Shekhar Challa; U.S. Senator Roger Marshall via video; Topeka Mayor Michael Padilla; Aaron Mays, Chairman of the Shawnee County Board of Commissioners; and John Mugler, District Director, Office of Senator Marshall. In addition, Kansas Governor Laura Kelly issued a gubernatorial proclamation declaring June 8 – 14 "Kansas Nonmelanoma Skin Cancer Awareness Week," noting that KMC Dermatology is the first practice in the state of Kansas to offer Image-Guided SRT. Kerwin Brandt, chief executive officer of Chicago-based SkinCure Oncology, said, "We are delighted to partner with KMC Dermatology to offer this highly effective, noninvasive treatment option for their patients. It is critical that patients everywhere have the choice of treating their nonmelanoma skin cancer without surgery." About SkinCure OncologySkinCure Oncology is the industry leader in providing a comprehensive model for the delivery of Image-Guided Superficial Radiation Therapy (Image-Guided SRT or IGSRT), the most advanced nonsurgical treatment for common skin cancer. The company partners with quality-focused dermatologists, Mohs surgeons and other physicians to bring cancer center-level radiation therapy treatment to private practices. Presented to patients as the GentleCure Experience™, Image-Guided SRT is available from some 500 physicians nationwide, with more than 100,000 patients having been treated. Learn more about the company at and visit for helpful consumer and patient information. Media Contact:Matt RussellRussell Public Communications520-232-9840mrussell@ View original content to download multimedia: SOURCE SkinCure Oncology Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
